Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
Background:To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC).Methods:154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumour...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 October 2016
|
| In: |
British journal of cancer
Year: 2016, Jahrgang: 115, Heft: 10, Pages: 1215-1222 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/bjc.2016.343 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1038/bjc.2016.343 Verlag, Volltext: https://www.nature.com/articles/bjc2016343 
|
| Verfasserangaben: | Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Kelly S. Oliner, Michael Boedigheimer, Brian Twomey, Ying Zhang, Gaston Demonty and Claus-Henning Köhne |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666435287 | ||
| 003 | DE-627 | ||
| 005 | 20230426220512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190528s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bjc.2016.343 |2 doi | |
| 035 | |a (DE-627)1666435287 | ||
| 035 | |a (DE-599)KXP1666435287 | ||
| 035 | |a (OCoLC)1341225566 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Karthaus, Meinolf |e VerfasserIn |0 (DE-588)110269357 |0 (DE-627)537491910 |0 (DE-576)289668204 |4 aut | |
| 245 | 1 | 0 | |a Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer |c Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Kelly S. Oliner, Michael Boedigheimer, Brian Twomey, Ying Zhang, Gaston Demonty and Claus-Henning Köhne |
| 264 | 1 | |c 20 October 2016 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.05.2019 | ||
| 520 | |a Background:To investigate tumour biomarker status and efficacy of first-line panitumumab+FOLFIRI for metastatic colorectal carcinoma (mCRC).Methods:154 patients received first-line panitumumab + FOLFIRI every 14 days. Primary end point was objective response rate (ORR). Data were analysed by tumour RAS (KRAS/NRAS) and BRAF status, and baseline amphiregulin (AREG) expression.Results:Objective responses occurred more frequently in RAS wild type (WT) (59%) vs RAS mutant (MT) (41%) mCRC and in RAS WT/BRAF WT (68%) vs RAS or BRAF MT (37%) disease. Median response duration was longer in RAS WT (13.0 months) vs RAS MT (5.8 months) (hazard ratio (HR): 0.16). Median progression-free survival was longer in RAS WT vs MT (11.2 vs 7.3 months; HR, 0.37) and was also longer in RAS WT/BRAF WT vs RAS or BRAF MT (13.2 vs 6.9 months; HR, 0.25). Incidence of adverse events was similar regardless of RAS/BRAF status, and no new safety signals were noted. Among patients with RAS WT tumours, ORR was 67% with high AREG expression and 38% with low AREG expression.Conclusions:First-line panitumumab+FOLFIRI was associated with favourable efficacy in patients with RAS WT and RAS WT/BRAF WT vs MT mCRC tumours and was well tolerated. | ||
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d Edinburgh : Nature Publ. Group, 1947 |g 115(2016), 10, Seite 1215-1222 |h Online-Ressource |w (DE-627)320420094 |w (DE-600)2002452-6 |w (DE-576)103746854 |x 1532-1827 |7 nnas |a Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer |
| 773 | 1 | 8 | |g volume:115 |g year:2016 |g number:10 |g pages:1215-1222 |g extent:8 |a Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1038/bjc.2016.343 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bjc2016343 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190528 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 999 | |a KXP-PPN1666435287 |e 3480024866 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer","title":"Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer"}],"language":["eng"],"id":{"eki":["1666435287"],"doi":["10.1038/bjc.2016.343"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"pubHistory":["Volume 1, issue 1 (1 March 1947)-"],"language":["eng"],"part":{"pages":"1215-1222","extent":"8","issue":"10","text":"115(2016), 10, Seite 1215-1222","year":"2016","volume":"115"},"title":[{"title_sort":"British journal of cancer","title":"British journal of cancer","subtitle":"BJC"}],"note":["Gesehen am 27.10.25"],"disp":"Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancerBritish journal of cancer","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2002452-6"],"issn":["1532-1827"],"eki":["320420094"]},"origin":[{"publisherPlace":"Edinburgh ; Edinburgh","dateIssuedDisp":"1947-","publisher":"Nature Publ. Group ; Churchill Livingstone","dateIssuedKey":"1947"}],"recId":"320420094","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"BJC"}]}],"note":["Gesehen am 28.05.2019"],"recId":"1666435287","origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"20 October 2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Karthaus, Meinolf","role":"aut","given":"Meinolf","family":"Karthaus"},{"display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut","family":"Hofheinz"}],"name":{"displayForm":["Meinolf Karthaus, Ralf-Dieter Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Kelly S. Oliner, Michael Boedigheimer, Brian Twomey, Ying Zhang, Gaston Demonty and Claus-Henning Köhne"]}} | ||
| SRT | |a KARTHAUSMEIMPACTOFTU2020 | ||